Hangzhou Tigermed Consulting Co (SZSE:300347) 3-Year EBITDA Growth Rate : 3.70% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Hangzhou Tigermed Consulting Co 3-Year EBITDA Growth Rate?

Hangzhou Tigermed Consulting Co's EBITDA per Share for the three months ended in Dec. 2023 was ¥1.39.

During the past 12 months, Hangzhou Tigermed Consulting Co's average EBITDA Per Share Growth Rate was -0.70% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 3.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 30.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 41.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hangzhou Tigermed Consulting Co was 92.70% per year. The lowest was 3.70% per year. And the median was 34.15% per year.

Competitive Comparison of Hangzhou Tigermed Consulting Co's 3-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hangzhou Tigermed Consulting Co's 3-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's 3-Year EBITDA Growth Rate falls into.

Hangzhou Tigermed Consulting Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Hangzhou Tigermed Consulting Co (SZSE:300347) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Hangzhou Tigermed Consulting Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Tigermed Consulting Co (SZSE:300347) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (SZSE:300347) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

HNGZY:USA 03347:Hong Kong

Address

Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053

Website

https://www.tigermed.net

Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.

Hangzhou Tigermed Consulting Co (SZSE:300347) Headlines

No Headlines